...
首页> 外文期刊>Journal of neurology >Reply to D. S. Goodinin J Neurol (2006) 253:947-948
【24h】

Reply to D. S. Goodinin J Neurol (2006) 253:947-948

机译:回复D.S. Goodinin J Neurol(2006)253:947-948

获取原文
获取原文并翻译 | 示例
           

摘要

Sirs: I, together with the coauthors, have read with interest the comments made by Dr. Goodin on our recent paper published in your journal. In response to the comments, it is obvious that the results in our paper are not from a randomised, controlled, double-blind study. Instead, our aim was actually not to perform a comparative efficacy study, but as the paper points out, the objective was rather to describe in an observational manner the behaviour of a cohort of relapsing-remitting multiple sclerosis patients treated with different formulations of interferon beta in daily clinical practice . Although a proportion of patients were also followed up for 6,7 and 8 years, we report data from 168 patients on decrease in relapse rate during the first 5 years of follow-up. It is important to note that the maximum number of treated patients in a clinical trial withinterferon for a period of 5 years was just 56 .
机译:先生:我和合著者一起读了古丁博士对我们最近发表在您期刊上的论文的评论。在回应这些评论时,很明显,我们论文的结果并非来自随机,对照,双盲研究。相反,我们的目的实际上不是进行比较功效研究,而是如论文所指出的,目的是以观察方式描述一组接受不同干扰素β治疗的复发缓解型多发性硬化症患者的行为。在日常临床实践中。尽管也对一部分患者进行了6.7年和8年的随访,但我们报告了168位患者在随访的前5年中复发率降低的数据。重要的是要注意,在一项为期5年的干扰素临床试验中,接受治疗的最大患者人数仅为56。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号